Competition between brand‐name and generics – analysis on pricing of brand‐name pharmaceutical

Ying Kong

Health Economics, 2009, vol. 18, issue 5, 591-606

Abstract: The objective of this paper is to provide two‐stage game models explaining the ‘Generic Competition Paradox’ that demonstrates an increase of brand‐name drug price in response to generic entry. Under the assumption that there are two groups of consumers who are segmented by their insurance status, high insurance coverage and low insurance coverage consumers, the models indicate that the decisive factor is the market share of the high insurance coverage consumer and the size of cross‐substitute factor relative to certain characteristics of market demand. The paper analyses both the case of only true generic entry and the case of pseudo‐generic and true generic entry. The models prove that a brand‐name price will increase when both the market share of high insurance coverage consumer and the factor of cross‐substitute are small. Also, the ‘Generic Competition Paradox’ more likely occurs in the market where less pseudo‐generic products are produced. Copyright © 2008 John Wiley & Sons, Ltd.

Date: 2009
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (4)

Downloads: (external link)
https://doi.org/10.1002/hec.1392

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:wly:hlthec:v:18:y:2009:i:5:p:591-606

Access Statistics for this article

Health Economics is currently edited by Alan Maynard, John Hutton and Andrew Jones

More articles in Health Economics from John Wiley & Sons, Ltd.
Bibliographic data for series maintained by Wiley Content Delivery ().